OBJECTIVE: To investigate the use of glucocorticoids (GCs) and related adverse events (AEs) in a long-term, geographically defined cohort of patients with polymyalgia rheumatica (PMR). METHODS: Using a population-based inception cohort, details of GC therapy were abstracted from medical records of all patients diagnosed with PMR in 2000-2014. Age- and sex-matched comparators without PMR were identified from the same underlying population. Cumulative and daily dosage of GC, rate of disease relapse, occurrence of GC-related AEs, and rate of GC discontinuation were analyzed. RESULTS: The study included 359 patients with PMR and 359 comparators. The median time to taper below 5 mg/day for 6 months was 1.44 years (95% confidence interval [95% CI] 1.36-1.62), while the median time to permanent discontinuation was 5.95 years (95% CI 3.37-8.88). The mean ± SD cumulative dose of GC at 2 and 5 years was 4.0 ± 3.5 grams and 6.3 ± 9.8 grams, respectively. The mean ± SD daily dose of GC at 2 and 5 years was 6.1 ± 7.6 mg/day and 7.2 ± 9.5 mg/day, respectively. There were no differences in rates of AEs between patients with PMR and comparators for diabetes mellitus, hypertension, hyperlipidemia, or hip, vertebral, or Colles fractures (P > 0.2 for all). Cataracts were more common in patients with PMR than comparators (hazard ratio 1.72 [95% CI 1.23-2.41]). CONCLUSION: Relapse rates in PMR are highest in the early stages of therapy. Despite often protracted therapy, with the exception of cataracts, the rates of studied morbidities linked to GC are not more common in PMR than comparators.
OBJECTIVE: To investigate the use of glucocorticoids (GCs) and related adverse events (AEs) in a long-term, geographically defined cohort of patients with polymyalgia rheumatica (PMR). METHODS: Using a population-based inception cohort, details of GC therapy were abstracted from medical records of all patients diagnosed with PMR in 2000-2014. Age- and sex-matched comparators without PMR were identified from the same underlying population. Cumulative and daily dosage of GC, rate of disease relapse, occurrence of GC-related AEs, and rate of GC discontinuation were analyzed. RESULTS: The study included 359 patients with PMR and 359 comparators. The median time to taper below 5 mg/day for 6 months was 1.44 years (95% confidence interval [95% CI] 1.36-1.62), while the median time to permanent discontinuation was 5.95 years (95% CI 3.37-8.88). The mean ± SD cumulative dose of GC at 2 and 5 years was 4.0 ± 3.5 grams and 6.3 ± 9.8 grams, respectively. The mean ± SD daily dose of GC at 2 and 5 years was 6.1 ± 7.6 mg/day and 7.2 ± 9.5 mg/day, respectively. There were no differences in rates of AEs between patients with PMR and comparators for diabetes mellitus, hypertension, hyperlipidemia, or hip, vertebral, or Colles fractures (P > 0.2 for all). Cataracts were more common in patients with PMR than comparators (hazard ratio 1.72 [95% CI 1.23-2.41]). CONCLUSION: Relapse rates in PMR are highest in the early stages of therapy. Despite often protracted therapy, with the exception of cataracts, the rates of studied morbidities linked to GC are not more common in PMR than comparators.
Authors: Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson Journal: Arthritis Rheum Date: 2012-04
Authors: Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton Journal: Mayo Clin Proc Date: 2012-11-28 Impact factor: 7.616
Authors: Christian Dejaco; Yogesh P Singh; Pablo Perel; Andrew Hutchings; Dario Camellino; Sarah Mackie; Andy Abril; Artur Bachta; Peter Balint; Kevin Barraclough; Lina Bianconi; Frank Buttgereit; Steven Carsons; Daniel Ching; Maria Cid; Marco Cimmino; Andreas Diamantopoulos; William Docken; Christina Duftner; Billy Fashanu; Kate Gilbert; Pamela Hildreth; Jane Hollywood; David Jayne; Manuella Lima; Ajesh Maharaj; Christian Mallen; Victor Martinez-Taboada; Mehrdad Maz; Steven Merry; Jean Miller; Shunsuke Mori; Lorna Neill; Elisabeth Nordborg; Jennifer Nott; Hannah Padbury; Colin Pease; Carlo Salvarani; Michael Schirmer; Wolfgang Schmidt; Robert Spiera; David Tronnier; Alexandre Wagner; Madeline Whitlock; Eric L Matteson; Bhaskar Dasgupta Journal: Arthritis Rheumatol Date: 2015-10 Impact factor: 10.995
Authors: Christian Dejaco; Yogesh P Singh; Pablo Perel; Andrew Hutchings; Dario Camellino; Sarah Mackie; Eric L Matteson; Bhaskar Dasgupta Journal: Ann Rheum Dis Date: 2015-10 Impact factor: 19.103
Authors: Adam T Hancock; Christian D Mallen; Sara Muller; John Belcher; Edward Roddy; Toby Helliwell; Samantha L Hider Journal: CMAJ Date: 2014-07-28 Impact factor: 8.262
Authors: Ciro Manzo; Ayar Nizama-Via; Marcin Milchert; Marco Isetta; Alberto Castagna; Maria Natale; Jordi Serra-Mestres Journal: Reumatologia Date: 2020-12-23
Authors: Sara Muller; Rebecca Whittle; Samantha L Hider; John Belcher; Toby Helliwell; Chris Morton; Emily Hughes; Sarah A Lawton; Christian D Mallen Journal: Rheumatology (Oxford) Date: 2020-08-01 Impact factor: 7.580
Authors: Richard Partington; Toby Helliwell; Sara Muller; Alyshah Abdul Sultan; Christian Mallen Journal: Arthritis Res Ther Date: 2018-11-20 Impact factor: 5.156